Morgan Stanley Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $40.00

Posted by George Bondi on Jul 25th, 2026

Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its target price trimmed by Morgan Stanley from $44.00 to $40.00 in a report published on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other research firms also recently commented on CLDX. UBS Group lifted their price target on Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. HC Wainwright restated a “buy” rating and set a $42.00 price objective on shares of Celldex Therapeutics in a research note on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Friday, July 17th. Wells Fargo & Company increased their target price on Celldex Therapeutics from $38.00 to $54.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Finally, Barclays lifted their target price on Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $52.77.

Read Our Latest Report on CLDX

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $35.28 on Wednesday. Celldex Therapeutics has a 12 month low of $19.72 and a 12 month high of $40.30. The company has a market capitalization of $2.77 billion, a price-to-earnings ratio of -8.28 and a beta of 0.90. The company’s fifty day moving average price is $33.64 and its two-hundred day moving average price is $30.68.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.80 million. As a group, analysts anticipate that Celldex Therapeutics will post -4.36 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Handelsbanken Fonder AB grew its position in shares of Celldex Therapeutics by 5.0% during the 2nd quarter. Handelsbanken Fonder AB now owns 27,200 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 1,300 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in Celldex Therapeutics by 438.3% in the second quarter. Assenagon Asset Management S.A. now owns 788,696 shares of the biopharmaceutical company’s stock worth $29,347,000 after acquiring an additional 642,171 shares during the last quarter. Apella Capital LLC lifted its holdings in Celldex Therapeutics by 56.6% in the second quarter. Apella Capital LLC now owns 26,658 shares of the biopharmaceutical company’s stock worth $1,064,000 after acquiring an additional 9,634 shares during the last quarter. Mirador Capital Partners LP boosted its stake in Celldex Therapeutics by 1.7% in the second quarter. Mirador Capital Partners LP now owns 181,054 shares of the biopharmaceutical company’s stock valued at $6,737,000 after acquiring an additional 3,001 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new position in Celldex Therapeutics in the first quarter valued at approximately $929,000.

Celldex Therapeutics Company Profile

(Get Free Report)

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.